NCT03579979 is a NA clinical trial of Methylene Blue in Sentinel Lymph Node, sponsored by Chinese Academy of Sciences.

Who is sponsoring NCT03579979?

NCT03579979 is sponsored by Chinese Academy of Sciences.

What drugs are being tested in NCT03579979?

Interventions in NCT03579979: Methylene Blue, Indocyanine Green.

What condition does NCT03579979 study?

NCT03579979 studies Sentinel Lymph Node, Breast Cancer.

Is NCT03579979 still recruiting?

NCT03579979 is currently completed. Last updated 4 August 2021.

Last reviewed 2021-08-04 · How we verify

NCT03579979

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG

Completed NA Last updated 4 August 2021

What this trial tests

NA trial testing Methylene Blue in Sentinel Lymph Node in 130 participants. Completed in 19 August 2020.

Timeline

24 August 2017

Primary endpoint
30 August 2019

19 August 2020

Quick facts

Lead sponsor	Chinese Academy of Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	130
Start date	24 August 2017
Primary completion	30 August 2019
Estimated completion	19 August 2020
Sites	1 location across China

Drugs / interventions tested

Methylene Blue (METHYLENE BLUE) — full drug profile →
Indocyanine Green (INDOCYANINE GREEN) — full drug profile →

Conditions studied

Sentinel Lymph Node — all drugs for Sentinel Lymph Node →
Breast Cancer — all drugs for Breast Cancer →

Sponsor

Chinese Academy of Sciences — full company profile →

Who can join

Adults 18 to 75, female only, with Sentinel Lymph Node or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is a prospective, multicenter, self-controlled clinical study. In order to meet the requirements of this plan, 130 breast cancer patients need the sentinel lymph node biopsy with novel near-infarred fluorescence imaging system produced by Beijing digital precision medical technology co., LTD. The fluorescence molecular imaging of indocyanine green (ICG) on imaging detection and the control group, routine medical using methylene blue test .The safety and efficacy of fluorescence and staining in sentinel lymph node biopsy of breast cancer were compared.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interventional NIR Fluorescence Imaging of Cancer: Review on Next Generation of Dye-Loaded Protein-Based Nanoparticles for Real-Time Feedback During Cancer Surgery.
Borlan R, Focsan M, Maniu D, Astilean S. · · 2021 · cited 27× · PMID 33746512 · DOI 10.2147/ijn.s295234

Verify or expand the search:

Other trials of Methylene Blue

Trials testing the same drug.

NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07494773 — Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection · Phase 1, PHASE2 · not yet recruiting
NCT07040540 — Hemodynamic Effects of Intradermal Methylene Blue During Breast Surgery Under General Anesthesia · completed
NCT07169487 — Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study · Phase 1 · recruiting
NCT06900140 — Adjunctive Methylene Blue in Septic Shock · Phase 3 · completed

Other recruiting trials for Sentinel Lymph Node

Currently open trials in the same condition.

NCT07040657 — Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometria · NA · recruiting
NCT07154563 — Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Ca · recruiting
NCT06652672 — Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma · NA · recruiting
NCT06713161 — Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Sta · recruiting
NCT06259513 — Omission of Axillary Surgery in Breast Cancer Patients · NA · recruiting

Other Chinese Academy of Sciences trials

Trials by the same sponsor.

NCT07170345 — Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion · recruiting
NCT07158372 — Research on Identifying Critical Surgical Anatomy in Cholecystectomy Videos Based on Deep Learning · recruiting
NCT06989177 — Probiotic Intervention on Body Weight · NA · recruiting
NCT06989203 — Protein Supplementation Intervention on Body Weight · NA · recruiting
NCT06035250 — AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03579979 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Sciences
Last refreshed: 4 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03579979.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing